Your browser doesn't support javascript.
loading
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models.
Daouti, Sherif; Higgins, Brian; Kolinsky, Kenneth; Packman, Kathryn; Wang, Huisheng; Rizzo, Christine; Moliterni, John; Huby, Nicholas; Fotouhi, Nader; Liu, Mei; Goelzer, Petra; Sandhu, Harpreet K; Li, Jia Kui; Railkar, Aruna; Heimbrook, David; Niu, Huifeng.
Affiliation
  • Daouti S; Discovery Oncology, Hoffmann-La Roche, Inc., Nutley, New Jersey 07110, USA.
Mol Cancer Ther ; 9(1): 134-44, 2010 Jan.
Article in En | MEDLINE | ID: mdl-20053779
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylbutyrates / Xenograft Model Antitumor Assays / Imidazolidines / MAP Kinase Kinase 1 / MAP Kinase Kinase 2 / Protein Kinase Inhibitors Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2010 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylbutyrates / Xenograft Model Antitumor Assays / Imidazolidines / MAP Kinase Kinase 1 / MAP Kinase Kinase 2 / Protein Kinase Inhibitors Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2010 Document type: Article Affiliation country: Country of publication: